Meeting
2019 ASCO Annual Meeting
Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET).
Authors
Cynthia Huang Bartlett
Pfizer Inc, Collegeville, PA
Cynthia Huang Bartlett , Jack Mardekian , Michelle Yu-Kite , Matthew James Cotter , Sindy Kim , Jaclyn Decembrino , Tamara Snow , Kenneth R. Carson , Jillian Motyl Rockland , Albert L. Kraus , Keith D. Wilner , Norihiko Oharu , Patrick Schnell , Dongrui (Ray) Lu , Jennifer Tursi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1055)
DOI
10.1200/JCO.2019.37.15_suppl.1055
Abstract #
1055
Poster Bd #
136
Abstract Disclosures
Similar Posters
First Author: Gabrielle Betty Rocque
Poster
2023 ASCO Annual Meeting
First-line systemic treatment with palbociclib in women aged ≥70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program.
First Author: Elisabeth Carola
Poster
2023 ASCO Annual Meeting
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.
First Author: Tomás Pascual
Poster
2018 ASCO Annual Meeting
Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3.
First Author: Richard S. Finn